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Abstract Magnesium fulfils important roles in multiple
physiological processes. Accordingly, a tight regulation of
magnesium homeostasis is essential. Dysregulated mag-
nesium serum levels, in particular hypomagnesaemia, are
common in patients with chronic kidney disease (CKD)
and have been associated with poor clinical outcomes. In
cell culture studies as well as in clinical situations mag-
nesium levels were associated with vascular calcification,
cardiovascular disease and altered bone-mineral metabo-
lism. Magnesium has also been linked to diseases such as
metabolic syndrome, diabetes, hypertension, fatigue and
depression, all of which are common in CKD. The present
review summarizes and discusses the latest clinical data on
the impact of magnesium and possible effects of higher
levels on the health status of patients with CKD, including
an outlook on the use of magnesium-based phosphate-
binding agents in this context.
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Introduction
As the fourth most abundant cation in the body, magnesium
fulfils an important role in multiple physiological pro-
cesses. Over 300 enzymes require the presence of magne-
sium for their catalytic action, including many enzymes
utilising or synthesising ATP, or those that use other
nucleotides to synthesise DNA and RNA. While clinical
issues regarding magnesium disorders had received sur-
prisingly little attention until the 1990s, a shift in focus led
to some clinical investigations, especially in patients with
chronic kidney disease (CKD). In 2012, several reviews on
magnesium metabolism and disorders in magnesium bal-
ance were published in a special issue of the Clinical
Kidney Journal [1]. Given the growing interest in the
molecule since then the literature on the role of magnesium
in CKD has continued to accumulate substantially. For
instance, two cohort studies established hypomagnesaemia
as a predictor of mortality (Fig. 1) and kidney function
decline in CKD patients [2] as well as mortality in hae-
modialysis (HD) patients [3]. Furthermore, magnesium was
identified as an independent risk factor for non-recovery of
renal function in a cohort of critically ill patients with acute
kidney injury [4].
This review examines and reviews the clinical impact of
magnesium on the health status of CKD patients, in par-
ticular taking into account the influence of magnesium on
diseases such as metabolic syndrome, diabetes, hyperten-
sion, vascular calcification and cardiovascular events,
fatigue and depression all of which are frequently present
in CKD patients and/or contribute to CKD progress.
Magnesium and vascular calcification
Cardiovascular disease (CVD) is the leading cause of death
in the CKD population [5]. The high prevalence of vascular
calcification contributes significantly to this cardiovascular
risk [6]. The molecular mechanisms leading to vascular
calcification in CKD patients are still under investigation,
but there is consensus that it is an active, multifactorial,
cell-mediated and dynamic process [7, 8]. The progressive
loss of kidney function is accompanied by elevated serum
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fibroblast growth factor 23 (FGF23) levels, a decrease in
inorganic phosphate excretion and dysregulation of mineral
and bone metabolism. These disturbances promote vascular
calcification, whereby vascular smooth muscle cells
(VSMCs) play a central role in the pathogenesis by
undergoing an osteochondrogenic phenotype change in
response to elevated phosphate levels [9].
Several cell culture and animal studies suggest a pro-
tective role of magnesium through multiple molecular
mechanisms [10–12]. These results were extended by
recent studies in which magnesium was shown to inhibit
phosphate-induced calcification in vitro [13]. Moreover,
higher magnesium levels prevented calcification of bovine
VSMCs, inhibited expression of osteogenic proteins,
apoptosis and further progression of already established
calcification [14]. The first in vitro evidence in human
aortic VSMCs for a protective role of magnesium on
phosphate-induced calcification was based on the obser-
vation that living cells are necessary for magnesium ions to
exert its protective effect. These studies suggested a
potentially active intracellular role for magnesium ions in
attenuating the vascular calcification process [15]. Addi-
tionally, increasing magnesium concentrations improved
cell viability and normalised the cellular release of proteins
involved in vascular calcification [15]. Inhibition of the
Wnt/b-catenin signalling pathway was identified as one of
the intracellular mechanisms by which the anti-calcifying
effect of magnesium is achieved [16]. In the context of
these data, microcalcifications in human atherosclerotic
lesions contain both calcium and magnesium (in the form
of whitlockite and calcium phosphate/apatite); whereas
CKD- accelerated calcification was associated with a pre-
dominant deposition of calcium phosphate/apatite [17].
This suggests that in CKD, local magnesium homoeostasis
is disturbed and potentially aggravates vascular
calcifications.
The clinical relation between serum magnesium and
vascular changes including calcification was assessed in
several recent studies. A prospective study in 47 HD
patients revealed an association of magnesium serum
concentration with the intima–media thickness of carotid
arteries [13]. In addition, CKD patients with higher mag-
nesium serum concentrations had a significantly lower
pulse wave velocity (PWV). Similarly, a cohort study of
512 renal transplant recipients identified low magnesium
levels as a predictor of PWV and thus of vascular stiffness,
independent of clinically relevant covariates and especially
in older patients [18]. Furthermore, an observational cohort
study, investigating 283 CKD patients, reported an asso-
ciation of high magnesium levels with less endothelial
dysfunction [19].
So far, one double-blind, placebo-controlled randomised
trial examined the efficacy of oral magnesium oxide
(440 mg three times per week for 6 months) on endothelial
function in HD patients [20]. While magnesium supple-
mentation significantly decreased carotid intima–media
thickness, there were no significant effects on C-reactive
protein or flow-mediated dilatation, i.e. a functional
endothelial marker [20]. The study was limited by the
small sample size (less than 30 patients per treatment arm)
and a significant baseline imbalance in intima–media
thickness between the groups. Another small study in 47
dialysis patients randomised to no therapy or 610 mg
magnesium citrate orally every other day for 2 months also
noted a reduction of carotid intima–media thickness
accompanied by a reduction in PTH levels [21]. Thus,
more prospective interventional studies are warranted to
assess the potential benefits of magnesium supplementation
on vascular dysfunction and calcification.
Magnesium and CVD
A meta-analysis of 19 prospective studies including
532,979 participants found a significant inverse association
between magnesium intake and/or serum levels and the risk
of CVD events in different patient populations [22]. This
relationship was further sustained by a comprehensive
study in 7,216 Spanish high-risk patients for cardiovascular
disease. Again, an inverse association was noted between
dietary magnesium intake and all-cause mortality [23].
While the above studies did not focus on CKD patients,
several smaller studies did. In 80 diabetic CKD stage 2–4
patients, low serum magnesium was identified as a signif-
icant risk factor for an elevated pulse pressure, an estab-
lished marker for cardiovascular mortality [24]. Analyses
Fig. 1 Estimated survival probabilities in CKD patients with high
([2.2 mg/dL/[0.90 mmol/L), medium (1.8–2.2 mg/dL/
0.74–0.90 mmol/L) and low (\1.8 mg/dL/\0.74 mmol/L) serum
magnesium concentrations (adapted and reprinted from [2] with
permission from Elsevier)
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in 191 diabetics with CKD stage 1–3 have further under-
lined the relevance of this finding as lower magnesium
levels are associated with increased mortality and accel-
erated progression of renal disease [25]. A third observa-
tional cohort study in 283 CKD patients also identified
magnesium as an independent predictor of future cardio-
vascular outcomes [19]. In this study, Kaplan–Meier curves
showed significantly higher cardiovascular mortality rates
in CKD patients whose serum magnesium levels were
below 2.05 mg/dL (0.84 mmol/L). Finally, these results
were confirmed in a recent registry-based cohort study of
142,555 HD patients that again identified low serum
magnesium as a significant predictor of cardiovascular
mortality [3].
Thus, observational studies consistently identify low
serum magnesium levels as a predictor or risk factor of
vascular pathology, cardiovascular morbidity and all-cause
mortality. However, recent large-scale randomised clinical
trials [the Fourth International Study of Infarct Survival
(ISIS 4) and Magnesium in Coronaries (MAGIC)] in non-
renal patients could not prove a benefit of intravenous
magnesium after myocardial infarction, and magnesium
therapy is presently only indicated in patients with life-
threatening ventricular arrhythmias [26]. Whether the sit-
uation is different in CKD patients with ischaemic heart
disease remains to be tested.
Magnesium and bone-mineral metabolism
The association between magnesium and mineral metab-
olism was recently investigated in several animal studies.
To elucidate the effect of magnesium on phosphate ho-
moeostasis, rats were fed either a normal or magnesium-
deficient diet. Magnesium deficiency induced high serum
FGF23 levels, possibly contributing to the observed
decrease in renal phosphorus reabsorption [27]. While
direct effects of magnesium on FGF-23 are not well
established, the administration of a calcium acetate/mag-
nesium carbonate (CaMg) containing phosphate binder in
dialysis patients lowered both serum phosphate and FGF-
23 [28]; in another study magnesium oxide also lowered
FGF-23 levels in dialysis patients [29]; high magnesium
concentrations can also activate the calcium-sensing
receptor and thereby modulate PTH secretion in similar
manner to calcium, albeit less potently [30, 31]. Another
study demonstrated increasing serum 1,25-dihydroxyvita-
min D and decreasing PTH as well as phosphate levels in
response to magnesium loading in mouse models with
genetic inactivation of PTH or both, PTH and the cal-
cium-sensing receptor [32]. Both studies indicate the
importance of balanced magnesium intake in terms of
regulated phosphorus levels.
Since clinical studies have demonstrated the efficacy of
magnesium-containing phosphate binders [33], and in line
with the study by Quinn and colleagues [32], some concern
has arisen that high serum magnesium or magnesium
loading might oversuppress PTH secretion. In this context,
an in vitro study with intact rat parathyroid glands is of
importance, which showed that parathyroid glands were
sensitive to an inhibitory effect of magnesium only when a
moderately low calcium concentration was present [34].
The general dialysis population, however, does not have
low calcium concentrations; and this issue warrants more
clinical studies.
In addition to influencing PTH secretion, magnesium
affects the synthesis and metabolism of vitamin D [32].
Many epidemiologic studies suggest that low vitamin D
status may be associated with an increased risk of all-cause
mortality [35–37]. Importantly, the activities of three major
enzymes determining 25-hydroxyvitamin D3 (25(OH)D3)
level [38–41] and vitamin D-binding protein [39] are
magnesium dependent. Indeed, a cohort study including 12
157 NHANES III participants indicated that the inverse
associations between serum 25(OH)D3 and risk of mor-
tality could be modified by the intake level of magnesium
[42].
Although once again randomised controlled studies are
missing, the importance of magnesium for the mineral
metabolism seems likely.
Effects of magnesium on bone in uremic patients have
been reviewed recently [43]. In summary, various authors
have hypothesized that magnesium might contribute to
osteomalacia and/or renal osteodystrophy in particular via
suppressing PTH [43]. However, in vivo confirmation of
this in dialysis patients is lacking and there is at present no
conclusive evidence that magnesium administration in
CKD is associated with adynamic bone disease. Of note, in
the CALMAG trial, administration of a CaMg-containing
phosphate binder to dialysis patients did not affect markers
of bone turnover over 6 months [28]. Epidemiological
studies in non-CKD populations have linked magnesium
deficiency to low bone mass and osteoporosis [44].
Magnesium and hypertension
Previous studies on the risk of hypertension and ischae-
mic heart disease have shown only a modest effect [45–
48], or inconsistent results [49–54], regarding its corre-
lation to dietary magnesium intake (and serum magne-
sium levels). This was mainly due to a lack of direct
measures of actual magnesium uptake. Serum levels of
magnesium only correlate weakly with its intake unless
extreme conditions prevail (e.g. excessive oral adminis-
tration of magnesium salts) [55]. Thus, the use of urinary
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magnesium excretion as a more precise indicator of
dietary magnesium uptake might provide a better insight
into this association. In fact, results from a recent pro-
spective population-based cohort study with 5,511 par-
ticipants free of hypertension at baseline, demonstrated
that urinary magnesium excretion was inversely associ-
ated with the risk of developing hypertension [56]. The
same study group investigated the association between
magnesium uptake and ischaemic heart disease in 7,664
participants free from known CVD at baseline. Again,
low urinary magnesium excretion was independently
associated with a higher incidence risk [57]. The authors
suggest that an increased dietary magnesium intake, in
particular in those persons with a low urinary excretion
of magnesium, could reduce the risk of ischaemic heart
disease, lower blood pressure and prevent hypertension
[56, 57]. A recently published cross-sectional study,
involving 175 healthy subjects, supports the proposed
pathophysiological role of magnesium in the development
of hypertension: here a lower magnesium concentration
was the only significant parameter in a multivariate
analysis between pre-hypertensive and normotensive
subjects [58]. However, so far clinical trials have not
detected significant antihypertensive effects of magne-
sium supplementation alone [59] but rather suggest that
magnesium might augment the response to antihyperten-
sive drugs [60].
Magnesium and diabetes mellitus
Diabetes is the most frequent primary cause of CKD [61].
Hypomagnesaemia occurs with an incidence of 14–48 %
among patients with T2DM compared with 3–15 % among
their counterparts without diabetes [62]. A recent meta-
analysis of thirteen prospective cohort studies involving
536,318 participants and 24,516 cases of diabetes provided
further evidence that magnesium intake is inversely asso-
ciated with the risk of T2DM [relative risk (RR) 0.78
(95 % CI 0.73–0.84)] in a dose–response manner (Fig. 2)
[63]. Magnesium deficiency has also been linked to the
development of the disease as well as its severity: the lower
the magnesium level, the faster the deterioration of renal
function in patients with type 2 diabetes mellitus (T2DM)
[64].
Correction of hypomagnesaemia via dietary magnesium
supplementation improved glucose handling and insulin
response in elderly and non-insulin-dependent diabetics
[65] and improved insulin sensitivity as well as metabolic
control in T2DM patients with decreased serum magne-
sium levels [66]. The relationship between magnesium
intake and metabolic parameters was further investigated in
a cross-sectional study involving 210 elderly T2DM
patients, of which 89 % exhibited a low magnesium intake
and 37 % had overt hypomagnesaemia [67]. Metabolic
syndrome and depression were associated with low intake,
Fig. 2 Meta-analysis of prospective cohort studies examining mag-
nesium intake and the risk of developing type 2 diabetes. M male,
F female (adapted and reprinted from [63]. Copyright and all rights
reserved. Material from this publication has been used with the
permission of American Diabetes Association)
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but not metabolic parameters, such as HbA1c, low high-
density cholesterol, triglycerides and blood pressure.
In support of the well-known association between lower
serum magnesium levels and impaired renal function,
results from a cross-sectional study involving 51 T2DM
patients showed that CKD was accompanied by hypo-
magnesaemia including low intracellular magnesium con-
tent of red cells most likely as a result of low intake [68]. In
this study, magnesium deficiency was associated with poor
blood glucose control and thus a potential increased risk of
subsequent CVD events.
In line with this, T2DM is known to significantly
increase the risk of ventricular arrhythmias, which repre-
sent a serious issue in CKD patients [69]. Results from a
recent cross-sectional health survey among 750 adults with
high T2DM prevalence showed that in diabetics the odds
ratio of premature ventricular complexes was 0.24 (95 %
CI 0.06–0.98) if serum magnesium was above 0.70 mmol/
L compared to those where it was B0.70 mmol/L [70].
Thus, subnormal serum magnesium may be a contributor to
arrhythmias among patients with T2DM, and conceivably
magnesium supplementation in adults with T2DM may
confer protection against ventricular arrhythmias.
Despite the growing body of evidence on the relation
between hypomagnesaemia and insulin resistance in
T2DM, the molecular aetiology is poorly understood.
Transient receptor potential membrane melastatin
(TRPM)-6 is an ion channel which is crucial for magne-
sium homoeostasis and plays an essential role in epithelial
magnesium transport as well as in the active magnesium
reabsorption in the gut and kidney. Two rare single
nucleotide polymorphisms in TRPM6 (V1393I, K1584E)
conferred susceptibility for T2DM but only if magnesium
intake was low (\250 mg/day) [71]. Insulin stimulates
TRPM6 activity via elevating the cell surface expression of
TRPM6 but this mechanism fails with the above genetic
variants TRPM6 [72]. Thus, these studies identify a direct
molecular link between diabetes and magnesium and thus
potentially link magnesium homoeostasis to diabetic
outcomes.
Serum magnesium levels negatively correlated with
HbA1c, fasting plasma glucose and microalbuminuria [73].
To better elucidate the relationship between magnesium
deficiency and advanced T2DM nephropathy, a retrospec-
tive cohort study was conducted in 455 CKD patients.
Hypomagnesaemia was significantly associated with and
independently predicted progression to ESRD in patients
with T2DM nephropathy but not in those with non-diabetic
CKD [74]. In line with this observation, a later publication
linked magnesium concentrations to the rate of kidney
function decline [2]. However, in this latter study, the
effect of magnesium lost significance after adjustment for
additional covariates, in particular diuretics. Thus, whether
magnesium supplementation may delay the onset of T2DM
or its renal complications remains unknown at present.
Magnesium and fatigue/depression
Fatigue involves general, mental and physical fatigue
reduced motivation and reduced activity dimensions [75].
It is one of the most frequent dialysis-associated symptoms
with prevalences reported from 60 and up to 97 % [76].
Fatigue is often accompanied by depression, and major
depressive disorders are as well very common among CKD
and ESRD patients, affecting 20 % of CKD patients
compared to a prevalence of 2–10 % in the general popu-
lation [77]. The fact that only a minority of affected CKD
patients (*20 %) receives an adequate diagnosis and
treatment for depression, poses a major challenge for cli-
nicians to develop strategies to better understand and
manage depression in this population [77].
Basic research reveals the involvement of magnesium
ions in pathways which are connected to the known path-
ophysiology of depression. The N-methyl-D-aspartate
(NMDA)-ergic system received marked attention in the
context of developing new compounds for mood disorders
in recent years [78]. The magnesium ion is a naturally
occurring NMDA-receptor antagonist, and reduced intra-
cellular magnesium ions can be responsible for an
increased NMDA receptor sensitivity [79]. Besides NMDA
targets involved in the antidepressant action of magnesium,
there are brain-derived neurotrophic factors (BDNF) and
glycogen synthase kinase-3 (GSK-3). Magnesium increases
BDNF and both inhibit the activity of GSK-3, an enzyme
involved in the mechanisms of action of antidepressants
[80]. Magnesium is also a cofactor of tryptophan hydrox-
ylase, which catalyses serotonin synthesis. Hence levels of
serotonin and BDNF increase in the presence of magne-
sium, leading to an improvement of depressive symptoms.
Animal data indicated that short-term administration of
magnesium possesses potent antidepressant-like properties
in the forced swim test in mice [81]. No development of
tolerance was observed after prolonged treatment [82].
An early study in non-renal patients with chronic fatigue
indeed noted low intracellular magnesium levels, and
magnesium supplementation led to some clinical
improvement [83]. Further evidence was gained in one
randomised controlled trial comparing the efficacy of oral
magnesium supplementation with the standard antidepres-
sant imipramine in a 12-week treatment of newly diag-
nosed depression in twenty-three elderly with T2DM and
hypomagnesaemia. Here, oral magnesium supplementation
with MgCl2 (equivalent to 450 mg of elemental magne-
sium) was as effective as 50 mg imipramine daily, the
prototypic medication in depression [84]. However, of
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note, no magnesium study has so far specifically targeted
CKD-associated fatigue and depression. Given the paucity
of the safety data of currently available antidepressants in
CKD patients, magnesium supplementation—provided that
serum magnesium levels are controlled—could become a
safe therapeutic option in this population.
Conclusion
The clinical role of magnesium in terms of benefits and
harms of higher or lower serum magnesium levels con-
tinues to attract growing attention in research as evidenced
by the increasing literature available on this topic. In CKD
patients, vascular calcification, hypertension, diabetes, and
diabetic nephropathy are common comorbid situations
associated with increased mortality. All of these factors are
potentially affected by magnesium, and there is accumu-
lating evidence for beneficial effects of magnesium sup-
plementation and slightly elevated magnesium levels.
However, it is important to stress that in most studies
discussed above, causality cannot be inferred from the
associations reported. For example, many of the associa-
tions between magnesium intake and outcome may repre-
sent true relationships but also could be confounded by
magnesium intake reflecting different general dietary and/
or life-style habits. As such, we need intervention studies to
confirm or refute the hypotheses derived from these
associations.
In particular indications, such intervention studies
already exist. Thus, in hyperphosphataemia associated with
advanced CKD, phosphate binders are often necessary to
limit dietary phosphate absorption. Here, the combination
of calcium acetate and magnesium carbonate has been
shown to be as efficient and equally well tolerated as se-
velamer hydrochloride [33] in addition to reducing calcium
intake compared to pure calcium-based phosphate binders
[85]. In an animal study, the ensuing mildly elevated
magnesium levels resulted in beneficial effects in terms of
calcification, PTH levels and survival [86]. Clinical data
further demonstrated that CaMg does not negatively
influence bone health and might even help to maintain it,
causing neither an overstimulation nor a suppression of
bone turnover (Fig. 3) [28]. In view of the above discus-
sion, therapy with CaMg in hyperphosphataemic CKD
patients offers the exciting option to also evaluate whether
the many pleiotropic actions of magnesium beneficially
influence health issues beyond bone mineral disease.
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